ailure, increased susceptibility to lung infections and thromboembolic diseases make IPF one the major causes of morbidity and mortality in pulmonary diseases ( 4 , 5 ). Despite being classified as a rare disease, approximately three million people have been diagnosed worldwide and an increasing trend in mortality rates renders the research on IPF increasingly relevant ( 3 ).
← all excerpts
Shared and unique transcriptomic signature genes and pathways among biopsy, peripheral blood mononuclear cells and bronchoalveolar lavage samples in IPF patients revealed using comparative meta-transcriptome analysis.
1
—
—